- Home
- SIGA vs AQST Comparison
SIGA vs AQST Comparison
Compare SIGA & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SIGA | AQST |
|---|---|---|
| Founded | 1995 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 421.8M | 809.3M |
| IPO Year | 1997 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SIGA | AQST |
|---|---|---|
| Price | $6.45 | $6.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 374.9K | ★ 2.4M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | ★ 9.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | ★ $172,249,641.00 | $43,397,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $132.36 | $52.69 |
| P/E Ratio | $6.27 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.95 | $2.12 |
| 52 Week High | $9.62 | $7.55 |
Technical Indicators
Market Signals| Indicator | SIGA | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 48.09 | 52.76 |
| Support Level | $6.13 | $5.99 |
| Resistance Level | $6.55 | $6.44 |
| Average True Range (ATR) | 0.21 | 0.32 |
| MACD | 0.14 | 0.03 |
| Stochastic Oscillator | 86.81 | 54.73 |
Price Performance
Historical ComparisonAbout SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.